Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension

Thorax

Volumn 62, Issue 7, 2007, Pages 617-622

  Suntharalingam, Jay ^a   Machado, Rajiv D ^b   Sharples, Linda D ^a,c   Toshner, Mark R ^a   Sheares, Karen K ^a   Hughes, Rodney J ^a   Jenkins, David P ^a   Trembath, Richard C ^b   Morrell, Nicholas W ^d   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2;

ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; FEMALE; HEMODYNAMICS; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEX DIFFERENCE; SURVIVAL; THROMBOEMBOLISM;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY EMBOLISM; SURVIVAL ANALYSIS; VITAL CAPACITY;

EID: 34447323312     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.070680     Document Type: Article

References (40)

1. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113:2011- 20.
2. Riedel M, Stanek V, Widimsky J, et al. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982;81:151-8.
3. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
4. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003;76:1457-4.
5. Williamson TL, Kim NH, Rubin U. Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis 2002;45:203-12.
6. Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterecfomy. J Thorac Cardiovasc Surg 2002;124:1203-11.
7. Simonneau G, Galie N, Rubin U, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5-12S.
8. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001;68:92-102.
9. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-5.
10. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24.
11. Caslin AW, Heath D, Madden B, et al. The histopathology of 36 cases of plexogenic pulmonary arteriopathy. Histopathology 1990;16:9-19.
12. Moser KM, Fedullo PF, Finkbeiner WE, et al. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995;91:741-5.
13. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993;103:685-92.
14. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J 2000;15:440-8.
15. Peacock AJ. Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more? Thorax 2005;60:983-4.
16. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001;119:818-23.
17. Coulden R. State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:577-83.
18. Remy-Jardin M, Remy J, Wattinne L, et al. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold technique-comparison with pulmonary angiography. Radiology 1992;185:381-7.
19. Bergin CJ, Rios G, King MA, et al. Accuracy of high-resolution CT in identifying chronic pulmonary thromboembolic disease. AJR Am J Roentgenol 1996;166:1371-7.
20. Bonderman D, Jakowitsch J, Adlbrecht C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005;93:512-6.
21. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
22. Jais X, loos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005;60:1031-4.
23. Fedullo PF, Rubin U, Kerr KM, et al. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J 2000;15:435-7.
24. Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003;348:500-9.
25. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002;20:518-23.
26. Roberts KE, McElroy JJ, Wong WP, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital neart disease. Eur Respir J 2004;24:371-4.
27. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003;167:889-94.
28. Grant BJ, Lieber BB. Clinical significance of pulmonary arterial input impedance. Eur Respir J 1996;9:2196-9.
29. Burke CM, Glanville AR, Morris AJ, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987;42:131-5.
30. Morris TA, Auger WR, Ysrael MZ, et al. Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. Chest 1996;110:399-403.
31. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
32. Steenhuis LH, Groen HJ, Koeter GH, et al. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J 2000;16:276-81.
33. Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2599-603.
34. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167:1139-41.
35. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
36. Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2363-7.
37. Hughes R, George P, Parameshwar J, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension (letter). Thorax 2005;60:707.
38. Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28:138-43.
39. D'Alonzo. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9.
40. Hodgkins D, Sharples LC, Fowler SJ, et al. Survival in pulmonary hypertension: the Papworth experience. Amercian Thoracic Society Conference 2005:A802.